STOCK TITAN

Kestra Medical CEO sells shares in two Nov. 18 trades

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Kestra Medical Technologies, Ltd. (KMTS) director and President and Chief Executive Officer Brian Daniel Webster sold 11,715 common shares at a weighted average price of $28.2837 per share and 3,285 common shares at $29.0951 per share on November 18, 2026. Both sales were made pursuant to a Rule 10b5-1 trading plan adopted on July 21, 2026.

Insider Webster Brian Daniel
Role See Remarks
Sold 15,000 shs ($427K)
Type Security Shares Price Value
Sale Common Shares F1, F2 11,715 $28.2837 $331K
Sale Common Shares F1, F3 3,285 $29.0951 $96K
Holdings After Transaction: Common Shares — 430,215 shares (Direct)
Footnotes (3)
  1. F1. The reported transaction occurred pursuant to a Rule 10b5-1 trading plan adopted on July 21, 2026.
  2. F2. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $27.7927 to $28.7900. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.
  3. F3. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $28.8300 to $29.2950. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.
Shares sold 11,715 common shares November 18, 2026 sale
Weighted average sale price $28.2837 per share 11,715-share sale on November 18, 2026
Shares sold 3,285 common shares November 18, 2026 sale
Weighted average sale price $29.0951 per share 3,285-share sale on November 18, 2026
Rule 10b5-1 trading plan regulatory
"a Rule 10b5-1 trading plan adopted on July 21, 2026"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price in Column 4 is a weighted average price"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many KMTS shares did Brian Daniel Webster sell, and at what prices?

Brian Daniel Webster, Kestra Medical Technologies’ President and Chief Executive Officer, reported sales of 11,715 shares at $28.2837 per share and 3,285 shares at $29.0951 per share on November 18, 2026. The reported prices were weighted averages; the respective sale-price ranges were $27.7927 to $28.7900 and $28.8300 to $29.2950. Both sales were made under a Rule 10b5-1 trading plan adopted on July 21, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Webster Brian Daniel

(Last)(First)(Middle)
3933 LAKE WASHINGTON BLVD NE, SUITE 200

(Street)
KIRKLAND WASHINGTON 98033

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
KESTRA MEDICAL TECHNOLOGIES, LTD. [ KMTS ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
See Remarks
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/18/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Shares11/18/2026S(1)11,715D$28.2837(2)433,500D
Common Shares11/18/2026S(1)3,285D$29.0951(3)430,215D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The reported transaction occurred pursuant to a Rule 10b5-1 trading plan adopted on July 21, 2026.
2. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $27.7927 to $28.7900. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.
3. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $28.8300 to $29.2950. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.
Remarks:
President and Chief Executive Officer
/s/ Brian Daniel Webster11/19/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading